Analysis of FDA-approved imaging agents

Barker, 1899 Tuffier, 1929, Etat actuel de la chirurgie intra thoracique, Br. Med. J., 2, 879 Pollack, 1999, History of lodinated contrast media, 3 Muller, 1926, Experimental bone marrow reactions: I: Anemia produced by collargol, J. Exp. Med., 43, 533, 10.1084/jem.43.4.533 Burns, 1915, Thorium: a new agent for pyelography: preliminary report, JAMA, 64, 2126, 10.1001/jama.1915.02570520020005 Casper, 1967, The introduction in 1928-29 of thorium dioxide in diagnostic radiology, Ann. N.Y. Acad. Sci., 145, 527, 10.1111/j.1749-6632.1967.tb50255.x Swick, 1930, Intravenous urography by means of the sodium salt of 5-iodo2-pyridon-N-acetic acid, JAMA, 95, 1403, 10.1001/jama.1930.02720190015004 Kinch, 2014, An overview of FDA-approved new molecular entities: 1827–2013, Drug Discov. Today, 19, 1033, 10.1016/j.drudis.2014.03.018 Basu, 2008, Unparalleled contribution of 18F-FDG PET to medicine over 3 decades, J. Nucl. Med., 49, 17N Parker, 2017, Patterns of recurrence after postprostatectomy fossa radiation therapy identified by C-11 choline positron emission tomography/computed tomography, Int. J. Radiation Oncol. Biol. Physics, 97, 526, 10.1016/j.ijrobp.2016.11.014 Corot, 2013, Superparamagnetic iron oxide nanoparticles for MRI: contrast media pharmaceutical company R&D perspective, Wiley Interdiscipl. Rev. Nanomed. Nanobiotechnol., 5, 411, 10.1002/wnan.1225 Carroll, 1982, Ultrasonic contrast enhancement of tissue by encapsulated microbubbles, Radiology, 143, 747, 10.1148/radiology.143.3.7079504 Bokor, 2001, Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease, Invest. Radiol., 36, 104, 10.1097/00004424-200102000-00006 Singhal, 2013, The history of cerebral PET scanning: From physiology to cutting-edge technology, Neurology, 81, 1275, 10.1212/01.wnl.0000435802.68308.a1 Kinch, 2016, Innovator organizations in new drug development: assessing the sustainability of the biopharmaceutical industry, Cell Chem. Biol., 23, 644, 10.1016/j.chembiol.2016.05.013 Scannell, 2012, Diagnosing the decline in pharmaceutical R&D efficiency, Nat. Rev. Drug Discov., 11, 191, 10.1038/nrd3681 Munos, 2009, Lessons from 60 years of pharmaceutical innovation, Nat. Rev. Drug Discov., 8, 959, 10.1038/nrd2961 Pammolli, 2011, The productivity crisis in pharmaceutical R&D, Nat. Rev. Drug Discov., 10, 428, 10.1038/nrd3405 Murad, 2014, Image management systems, Gastrointestinal Endoscopy, 79, 15, 10.1016/j.gie.2013.07.048 Reardon, 2015, Alzheimer antibody drugs show questionable potentia, Nat. Rev. Drug Discov., 14, 591, 10.1038/nrd4709 Ringel, 2013, Does size matter in R&D productivity? If not, what does?, Nat. Rev. Drug Discov., 12, 901, 10.1038/nrd4164 Webster, 2014, Using mice to model Alzheimer’s dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models, Front. Genet., 5, 88, 10.3389/fgene.2014.00088 Saraceno, 2013, Modeling Alzheimer’s disease: from past to future, Front. Pharmacol., 4, 77, 10.3389/fphar.2013.00077 Kinders, 2007, Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice, Mol. Intervent., 7, 325, 10.1124/mi.7.6.9 Wang, 2015, Scientific and industrial challenges of developing nanoparticle-based theranostics and multiple-modality contrast agents for clinical application, Nanoscale, 7, 16146, 10.1039/C5NR03887A Nunn, 2006, The cost of developing imaging agents for routine clinical use, Invest. Radiol., 41, 206, 10.1097/01.rli.0000191370.52737.75